Paper Details

  1. Home
  2. Paper Details

Timely Genetic Testing and Therapy Management in Patients With g<i>BRCA</i>-Mutated Metastatic Breast Cancer Receiving Talazoparib.

Author: BarnettChad M, DonahueSarah, JonesTiffany, MartinezAshley, RyanJoanne C, SoussouElpitha L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study provides a hypothetical case study of a 42-year-old woman with triple-negative metastatic breast cancer (mBC) who is eligible for PARP inhibitor treatment. It highlights the importance of genetic testing to identify patients with gBRCA1/2 mutations who could benefit from talazoparib therapy. The study reviews the efficacy and safety of talazoparib and provides practical guidance on managing adverse events and drug interactions to optimize patient outcomes.
Paper Details　
Original Abstract of the Article :
Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that has demonstrated strong efficacy with manageable side effects for patients with germline breast cancer susceptibility genes 1 or 2 (g<i>BRCA1/2</i>)- mutated, human epidermal growth factor receptor 2-negative, locally advanced or met...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514123/

データ提供：米国国立医学図書館（NLM）

Timely Genetic Testing for gBRCA-Mutated Metastatic Breast Cancer

The diagnosis of metastatic breast cancer, a challenging journey through the desert of illness, can be further complicated by genetic mutations. This research emphasizes the importance of timely genetic testing for patients with gBRCA1/2 mutations, a key factor in guiding personalized treatment approaches. This study, like a well-equipped caravan, explores the use of talazoparib, a PARP inhibitor, for patients with these specific mutations.

Genetic Testing: A Navigational Tool for Personalized Cancer Care

This research highlights the crucial role of genetic testing in tailoring cancer treatment plans. Identifying gBRCA1/2 mutations can guide the use of PARP inhibitors, like talazoparib, leading to more effective and personalized therapy. This research is a testament to the power of precision medicine in the battle against cancer.

Navigating the Desert of Cancer: Empowering Patients with Genetic Information

This study encourages patients to be proactive in understanding their genetic makeup. By seeking genetic testing, patients can gain valuable information that can guide their treatment options and optimize their chances of success. This research empowers patients to actively participate in their healthcare journey, navigating the complex landscape of cancer with greater knowledge and informed decision-making.

Dr. Camel's Conclusion

This research is a beacon of hope in the desert of cancer treatment, emphasizing the importance of genetic testing in tailoring personalized care. It encourages patients to embrace the power of genetic information, a tool for navigating the complexities of treatment and enhancing their chances of successful outcomes.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-10-07
Further Info :

Pubmed ID

36199494

DOI: Digital Object Identifier

PMC9514123

Related Literature

Article Analysis
・Side Effects of talazoparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.